Literature DB >> 22231013

Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial.

Ensieh Shahrokh Tehraninejad1, Maryam Hafezi, Arezoo Arabipoor, Elham Aziminekoo, Mohammad Chehrazi, Akram Bahmanabadi.   

Abstract

PURPOSE: To compare the efficacy of cabergoline (Cb2) and intravenous human albumin (HA) in the prevention of ovarian hyperstimulation syndrome.
METHODS: In this randomized controlled trial study, 138 women who were at high risk for developing OHSS were randomly allocated into two groups. In Group one, 20 gr of HA 20% was infused over 1 h. Group two received 0.5 mg per day of Cb2 orally for 7 days, starting on oocyte pickup day. All patients were visited seven and 14 days after oocyte retrieval to determine early clinical or ultrasound evidence of OHSS.
RESULTS: Moderate OHSS was observed in 33 versus 14 cases in the HA and Cb2 groups, respectively, which was significantly different. The number of severe OHSS cases in the HA group was significantly higher than in the Cb2 group (P < 0.001).
CONCLUSIONS: Prophylactic oral low dose cabergoline was more effective and less costly than intravenous human albumin in the prevention of OHSS in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22231013      PMCID: PMC3288141          DOI: 10.1007/s10815-011-9708-4

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  18 in total

1.  Use of intramuscular progesterone versus intravenous albumin for the prevention of ovarian hyperstimulation syndrome.

Authors:  L Costabile; V Unfer; C Manna; S Gerli; D Rossetti; G C Di Renzo
Journal:  Gynecol Obstet Invest       Date:  2000       Impact factor: 2.031

Review 2.  Ovarian hyperstimulation syndrome: an update review.

Authors:  A Golan; R Ron-el; A Herman; Y Soffer; Z Weinraub; E Caspi
Journal:  Obstet Gynecol Surv       Date:  1989-06       Impact factor: 2.347

Review 3.  Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis.

Authors:  Mohamed A F M Youssef; Madelon van Wely; Mohamed Ahmed Hassan; Hesham Gaber Al-Inany; Monique Mochtar; Sherif Khattab; Fulco van der Veen
Journal:  Hum Reprod Update       Date:  2010-03-30       Impact factor: 15.610

4.  The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial.

Authors:  A Ben-Chetrit; T Eldar-Geva; M Gal; M Huerta; T Mimon; N Algur; Y Z Diamant; E J Margalioth
Journal:  Hum Reprod       Date:  2001-09       Impact factor: 6.918

Review 5.  Physiology and pathology of ovarian hyperstimulation syndrome.

Authors:  Raúl Gómez; Sergio R Soares; Cristiano Busso; Juan A Garcia-Velasco; Carlos Simón; Antonio Pellicer
Journal:  Semin Reprod Med       Date:  2010-11-16       Impact factor: 1.303

6.  Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study.

Authors:  O Gokmen; M Ugur; M Ekin; G Keles; C Turan; H Oral
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2001-06       Impact factor: 2.435

7.  Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study.

Authors:  A Z Isik; O Gokmen; H B Zeyneloglu; S Kara; G Keles; B Gulekli
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1996-12-27       Impact factor: 2.435

8.  Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome.

Authors:  Chin-Der Chen; Kuang-Han Chao; Jehn-Hsiahn Yang; Shee-Uan Chen; Hong-Nerng Ho; Yu-Shih Yang
Journal:  Fertil Steril       Date:  2003-07       Impact factor: 7.329

9.  Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study.

Authors:  José Bellver; Elkin A Muñoz; Agustín Ballesteros; Sérgio Reis Soares; Ernesto Bosch; Carlos Simón; Antonio Pellicer; José Remohí
Journal:  Hum Reprod       Date:  2003-11       Impact factor: 6.918

10.  Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study.

Authors:  Z Shoham; A Weissman; A Barash; R Borenstein; M Schachter; V Insler
Journal:  Fertil Steril       Date:  1994-07       Impact factor: 7.329

View more
  11 in total

1.  Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study.

Authors:  Aalie Torabizadeh; Fatemeh Vahidroodsari; Zakieh Ghorbanpour
Journal:  Iran J Reprod Med       Date:  2013-10

Review 2.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma Mourad; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2016-11-30

3.  Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome.

Authors:  L Rinaldi; F Lisi; H Selman
Journal:  J Endocrinol Invest       Date:  2014-01-08       Impact factor: 4.256

4.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma M Mourad; Aihua Wang; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2021-04-14

Review 5.  Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.

Authors:  Klaus Fiedler; Diego Ezcurra
Journal:  Reprod Biol Endocrinol       Date:  2012-04-24       Impact factor: 5.211

6.  Cabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study.

Authors:  Niyazi Kılıç; Özhan Özdemir; Hakan Cevdet Başar; Fadime Demircan; Fırat Ekmez; Oğuz Yücel
Journal:  Avicenna J Med       Date:  2015 Oct-Dec

Review 7.  Pharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-Analysis.

Authors:  Jun-Liang Guo; Duo-Duo Zhang; Yue Zhao; Dan Zhang; Xi-Meng Zhang; Can-Quan Zhou; Shu-Zhong Yao
Journal:  Sci Rep       Date:  2016-01-11       Impact factor: 4.379

8.  Evaluation of intravenous hydroxylethyl starch, intravenous albumin 20%, and oral cabergoline for prevention of ovarian hyperstimulation syndrome in patients undergoing ovulation induction.

Authors:  Ataollah Ghahiri; Neda Mogharehabed; Minoo Movahedi; Naeimehossadat Hosseini
Journal:  J Res Med Sci       Date:  2015-07       Impact factor: 1.852

Review 9.  Volume expanders for the prevention of ovarian hyperstimulation syndrome.

Authors:  Mohamed A Youssef; Selma Mourad
Journal:  Cochrane Database Syst Rev       Date:  2016-08-31

Review 10.  Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management.

Authors:  Bahia Namavar Jahromi; Mohammad Ebrahim Parsanezhad; Zahra Shomali; Pardis Bakhshai; Mahshid Alborzi; Najmeh Moin Vaziri; Zahra Anvar
Journal:  Iran J Med Sci       Date:  2018-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.